Apathy in patients with Alzheimer's disease is a cost‐driving factor

Background Apathy is the most frequent neuropsychiatric symptom in patients with dementia of the Alzheimer's type (DAT). We analyzed the influence of apathy on the resource use of DAT patients and their caregivers. Methods Included were baseline data of 107 DAT patients from a randomized clinical trial on apathy treatment. The Resource Utilization in Dementia (RUD) instrument assessed costs over a 1‐month period prior to baseline. Cost predictors were determined via a least absolute shrinkage and selection operator (LASSO). Results On average, total monthly costs were €3070, of which €2711 accounted for caregivers’ and €359 for patients’ costs. An increase of one point in the Apathy Evaluation Scale resulted in a 4.1% increase in total costs. Discussion Apathy is a significant cost driving factor for total costs in mild to moderate DAT. Effective treatment of apathy might be associated with reduced overall costs in DAT.